Fungal Surveillance in Bangladesh

Surveillance for Invasive Fungal Infections in Selected Hospitals in Dhaka City, Bangladesh

This will be an exploratory descriptive study designed to conduct surveillance for the identification of invasive fungal pathogens among hospitalized patients in Bangladesh at two tertiary care acute-level hospitals. including the Dhaka Medical College Hospital, the Dhaka Hospital of icddr,b, and the National Institute of Cancer Research Hospital (NICRH). Respiratory samples, blood, urine, cerebrospinal fluid, surgical wound infection swabs, and other samples including biopsy tissue specimens will be obtained at intensive care units, general medicine and surgery wards, post-operative care, etc. The collected specimens will be sent to the clinical microbiology laboratories of the surveillance hospitals or to the pathology laboratory (biopsy tissue specimens) to test for Aspergillus, Histoplasms, Candida, Pneumocystis, Cryptococcus, and Mucormycetes. The lab. methods will include microscopy, staining, culture, and biochemical tests mainly and if feasible then some specimens may undergo molecular or immunological methods.

Study Overview

• Status: Recruiting
• Conditions: Invasive Fungal Infections
• Intervention / Treatment: Other: Invasive Fungal disease surveillance

Detailed Description

1. Burden:

   Over 300 million people worldwide are infected with a deadly fungal infection, with 25 million at high risk of death or blindness. Population and disease demographics are used to calculate the worldwide burden of fungal diseases (age, gender, HIV infection, asthma, etc).

   Given the growing number of immunocompromised individuals especially among hospitalized patients who are at increased risk for invasive fungal infections, fungal illnesses require more attention than ever before. The importance of fungal diseases contributing to worldwide morbidity and mortality is emphasized. To assess the burden of these diseases more precisely, long-term, sustainable monitoring systems for fungal diseases, as well as better noninvasive and reliable diagnostic methods, are required.

   Even though most deaths from fungal illnesses are preventable, they are still a neglected topic by public health authorities. Other health issues, such as asthma, AIDS, cancer, organ transplantation, and corticosteroid therapy, can result in serious fungal infections. Antifungal therapy can be started right away if a correct diagnosis is made early. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually.

2. Knowledge gap:

Currently, there is no ongoing national surveillance system to detect invasive fungal pathogens or serious health threats. Hence, there is inadequate data on the burden, types, and diversity of fungal species in particular among hospitalized patients in Bangladesh. Some noteworthy issues affecting the proper diagnosis of invasive fungal pathogens in Bangladesh are an inadequate number of trained laboratory personnel to diagnose fungal diseases, only a few healthcare facilities performing fungal culture, insufficient awareness about severe fungal infections, lack of prioritization for fungal disease surveillance in healthcare delivery, lack of understanding about utilization of surveillance data to guide diagnosis and treatment, lack of antifungal drug stewardship and diagnostic stewardship and significant logistical challenges to ensure adequate biosecurity for diagnosis of and prevention against severe fungal infections.

Relevance:

Investigators need to take the necessary steps that will gradually lead to the establishment of a national surveillance system for invasive fungal pathogens, increase the generation of country-representative fungal surveillance data, improve surveillance data usage and reporting, and enhance IPC activities in Bangladesh.

Objectives:

To identify hospitalized patients infected with invasive fungal pathogens.

Description of the research project:

Methods:

This will be an exploratory descriptive study designed to conduct surveillance for the identification of invasive fungal pathogens among hospitalized patients in Bangladesh at two tertiary care acute-level hospitals.

The primary outcomes to be measured in this study:

The proportion of laboratory-identified invasive fungal pathogens among hospitalized patients.

• Study Type: Observational
• Enrollment (Estimated): 800

Contacts and Locations

• Study Contact: Name: Sayeeda Huq, MBBS, MIPH; Phone Number: +8801678127723; Email: sayeeda@icddrb.org
• Study Contact Backup: Name: Tanzir A Shuvo, MBBS,MPH,PhD; Phone Number: +8801816318802; Email: tanzir@icddrb.org

Study Locations

• Bangladesh
  • Dhaka, Bangladesh, 1212
    • Recruiting
    • International Centre for Diarrheal Disease Research, Bangladesh (icddr,b)
    • Contact: Sayeeda Huq, MBBS,MIPH; Phone Number: +8801678127723; Email: sayeeda@icddrb.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Hospitalized patients meeting the inclusion criteria and having ONE of the following groups of clinical features suggestive of infection of a particular organ system during sample collection:

• Clinical features suggestive of infection of the respiratory system:

  • Fever or chills WITH
  • Cough or shortness of breath WITH
  • Abnormal lung findings on chest auscultation or on chest X-ray or CT scans

• Clinical features of sepsis:

  • Hyperthermia or hypothermia (rectal temperature >38.5 Celsius or <35 Celsius respectively) and tachycardia plus either bounding pulses or, altered mental status or, hypoxemia in absence of pneumonia or, abnormal WBC count (>12×109 ⁄ L or, <4 ×109 ⁄ L or, band and neutrophil ratio ≥ 0.1) or, increased serum lactate level (diagnosed by physicians)

Description

Inclusion Criteria:

• Inclusion criteria:

Must include all of the following criteria:

1. Admitted/hospitalized patients of any age and gender in tertiary-level acute care hospitals AND

2. Having any of the following co-morbid immunosuppressive conditions or risk factors for healthcare-associated fungal infections such as:

   • Chronic lung conditions including asthma, COPD
   • Hemodialysis patients,
   • diabetes,
   • Patients receiving chemotherapy or immunosuppressive drugs (e.g. corticosteroids, immunosuppressive drugs among organ transplant recipients), for ≥7 days
   • Patients with AIDS
   • Patients at risk of healthcare-associated infections (e.g., Patients under postoperative care, having a urinary catheter, with tracheal intubation, under ventilatory support, secured with intravenous (IV) cannula, any other invasive procedures, etc.)
   • Hospitalized Patients under prolonged injectable antibiotic treatment (>7 days)
   • Prolonged hospitalization more than 7 days.
   • History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization

   AND

3. Patients or caregivers providing consent

For children aged <5 years, the age criteria and additional inclusion criteria will be as follows:

• 0 to 59-month-old children of either sex admitted in hospital with any illness.
• Have features of sepsis/pneumonia (based on clinical features below)

And any of the following criteria:

• Those who will fail to respond to injectable antibiotics or both 1st and 2nd line antibiotics (1st line- inj. Ampicillin plus gentamicin, 2nd line- inj. Ceftriaxone plus levofloxacin/gentamicin as per icddr,b hospital protocol)
• Any child with SAM or h/o recent measles or any condition that may induce immune suppression plus fail to respond to injectable antibiotics/ 1st line antibiotics (1st line antibiotics- inj. Ampicillin +inj. Gentamicin)
• Those who will develop late-onset hospital-associated infection (LOHAI)
• Any child who will require ICU care for more than 7 days
• Develop extensive thrush after taking long-term injectable antibiotics
• History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization

Exclusion Criteria:

• History of taking antifungal drugs within 2 weeks
• Not willing to give consent

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
child; identification and management of invasive fungal pathogen	Other: Invasive Fungal disease surveillance; Management of invasive fungal infection according to pathogen identification and susceptibility report.
adult; identification and management of invasive fungal pathogen	Other: Invasive Fungal disease surveillance; Management of invasive fungal infection according to pathogen identification and susceptibility report.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The proportion of laboratory-identified invasive fungal pathogens among hospitalized patients.	The primary goal will be to ensure a sustainable surveillance platform in low-income settings such as Bangladesh. The Investigators will utilize four strategies to establish a sustainable fungal surveillance platform/program in Bangladesh which will be as follows: Increase capacity to conduct surveillance; Identify and respond; Target and train; Monitor, evaluate and improve	July 2022 - September 2026

Collaborators and Investigators

• Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
• Collaborators: Centers for Disease Control and Prevention; Institute of Epidemiology, Disease Control and Research
• Investigators: Principal Investigator: Sayeeda Huq, MBBS,MIPH, International Centre for Diarrheal Diseases Research, Bangladesh

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2022
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): September 30, 2026

Study Registration Dates

• First Submitted: October 23, 2023
• First Submitted That Met QC Criteria: October 23, 2023
• First Posted (Actual): October 26, 2023

Study Record Updates

• Last Update Posted (Estimated): November 22, 2023
• Last Update Submitted That Met QC Criteria: November 20, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Surveillance; Hospitalized patients; Invasive Fungal Pathogen
• Additional Relevant MeSH Terms: Bacterial Infections and Mycoses; Infections; Mycoses; Invasive Fungal Infections
• Other Study ID Numbers: PR-21142

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No